These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10589007)

  • 41. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
    Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
    Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carrot allergy: double-blinded, placebo-controlled food challenge and identification of allergens.
    Ballmer-Weber BK; Wüthrich B; Wangorsch A; Fötisch K; Altmann F; Vieths S
    J Allergy Clin Immunol; 2001 Aug; 108(2):301-7. PubMed ID: 11496252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.
    Nony E; Bouley J; Le Mignon M; Lemoine P; Jain K; Horiot S; Mascarell L; Pallardy M; Vincentelli R; Leone P; Roussel A; Batard T; Abiteboul K; Robin B; de Beaumont O; Arvidsson M; Rak S; Moingeon P
    Allergy; 2015 Jul; 70(7):795-804. PubMed ID: 25846209
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
    Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
    Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterisation of recombinant isoforms of birch pollen allergen Bet v 1.
    Spangfort MD; Ipsen H; Sparholt SH; Aasmul-Olsen S; Osmark P; Poulsen FM; Larsen M; Mørtz E; Roepstorff P; Larsen JN
    Adv Exp Med Biol; 1996; 409():251-4. PubMed ID: 9095250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization.
    Movérare R; Westritschnig K; Svensson M; Hayek B; Bende M; Pauli G; Sorva R; Haahtela T; Valenta R; Elfman L
    Int Arch Allergy Immunol; 2002 Aug; 128(4):325-35. PubMed ID: 12218371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning.
    Swoboda I; Jilek A; Ferreira F; Engel E; Hoffmann-Sommergruber K; Scheiner O; Kraft D; Breiteneder H; Pittenauer E; Schmid E
    J Biol Chem; 1995 Feb; 270(6):2607-13. PubMed ID: 7852325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Folded or Not? Tracking Bet v 1 Conformation in Recombinant Allergen Preparations.
    Husslik F; Hanschmann KM; Krämer A; Seutter von Loetzen C; Schweimer K; Bellinghausen I; Treudler R; Simon JC; Vogel L; Völker E; Randow S; Reuter A; Rösch P; Vieths S; Holzhauser T; Schiller D
    PLoS One; 2015; 10(7):e0132956. PubMed ID: 26186356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
    Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
    Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of PR-10 genes from eight Betula species and detection of Bet v 1 isoforms in birch pollen.
    Schenk MF; Cordewener JH; America AH; Van't Westende WP; Smulders MJ; Gilissen LJ
    BMC Plant Biol; 2009 Mar; 9():24. PubMed ID: 19257882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant Bet v 1 vaccine for treatment of allergy to birch pollen.
    Grönlund H; Gafvelin G
    Hum Vaccin; 2010 Dec; 6(12):970-7. PubMed ID: 21157177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients.
    Nopp A; Halldén G; Lundahl J; Johansson E; Vrtala S; Valenta R; Grönneberg R; Van Hage-Hamsten M
    J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):101-9. PubMed ID: 10887312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1.
    Bauer L; Bohle B; Jahn-Schmid B; Wiedermann U; Daser A; Renz H; Kraft D; Ebner C
    Clin Exp Immunol; 1997 Mar; 107(3):536-41. PubMed ID: 9067529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.
    Ebner C; Schenk S; Najafian N; Siemann U; Steiner R; Fischer GW; Hoffmann K; Szépfalusi Z; Scheiner O; Kraft D
    J Immunol; 1995 Feb; 154(4):1932-40. PubMed ID: 7530747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IgE and allergen-specific immunotherapy-induced IgG
    Groh N; von Loetzen CS; Subbarayal B; Möbs C; Vogel L; Hoffmann A; Fötisch K; Koutsouridou A; Randow S; Völker E; Seutter von Loetzen A; Rösch P; Vieths S; Pfützner W; Bohle B; Schiller D
    Clin Exp Allergy; 2017 May; 47(5):693-703. PubMed ID: 27770477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Colonoscopic allergen provocation test with rBet v 1 in patients with pollen-associated food allergy.
    Pickert CN; Lorentz A; Manns MP; Bischoff SC
    Allergy; 2012 Oct; 67(10):1308-15. PubMed ID: 22913618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Responses of human birch pollen allergen-reactive T cells to chemically modified allergens (allergoids).
    Dormann D; Ebner C; Jarman ER; Montermann E; Kraft D; Reske-Kunz AB
    Clin Exp Allergy; 1998 Nov; 28(11):1374-83. PubMed ID: 9824410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice.
    Winkler B; Baier K; Wagner S; Repa A; Eichler HG; Scheiner O; Kraft D; Wiedermann U
    Clin Exp Allergy; 2002 Jan; 32(1):30-6. PubMed ID: 12002733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2.
    Ferreira FD; Mayer P; Sperr WR; Valent P; Seiberler S; Ebner C; Liehl E; Scheiner O; Kraft D; Valenta R
    J Allergy Clin Immunol; 1996 Jan; 97(1 Pt 1):95-103. PubMed ID: 8568143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.